NOT FOR RELEASE, DISTRIBUTION, PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Oxford, UK; 6th September 2018: Sensyne Health plc (LSE: SENS) (the “Company”), the British clinical AI technology company, today welcomes and signs up to the Department of Health and Social Care’s (DHSC) new code of conduct for data-driven health and care technologies as announced on the 5th September by Health Minister Lord O’Shaughnessy in a speech at the NHS Health and Care Innovation Expo conference.
Sensyne Health has made a series of recent announcements regarding its unique collaboration with three NHS trusts which enables the Company to analyse anonymised patient data using its Clinical AI technologies in order to accelerate the discovery and development of new medicines and improve patient care. This new code of conduct mirrors the principles of the Company. Sensyne Health is pleased to be able to sign up to the initial code and welcomes the opportunity to co-design the final version with the DHSC, due to be issued later this year.
LORD (PAUL) DRAYSON, CEO OF SENSYNE HEALTH, COMMENTED:
“The introduction of this code is an important step by the government in ensuring that all companies wishing to analyse NHS patient data do so ethically, transparently and for patient benefit. We are happy to sign up to this new code and welcome its introduction by the government.”
NOTES TO EDITORS:
The 10 headline principles of the initial code of conduct for data-driven technologies are:
- Define the user
- Define the value proposition
- Be fair, transparent and accountable about what data you are using
- Use data that is proportionate to the identified user need (data minimisation principle of GDPR)
- Make use of open standards
- Be transparent to the limitations of the data used and algorithms deployed
- Make security integral to the design
- Define the commercial strategy
- Show evidence of effectiveness for the intended use
- Show what type of algorithm you are building, the evidence base for choosing that algorithm, how you plan to monitor its performance on an ongoing basis and how you are validating performance of the algorithm.
FOR MORE INFORMATION PLEASE CONTACT:
Sensyne Health
www.sensynehealth.com
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Laura Steward, Head of Marketing
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
ABOUT SENSYNE HEALTH
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles and code of conduct , UK data protection law and applicable regulatory guidance.
Sensyne Health is listed on the Alternative Investment Market of the London Stock Exchange (SENS.L) and is based in the Big Data Institute at the University of Oxford's Old Road Campus.
For more information, please visit: www.sensynehealth.com
DISCLAIMER
This announcement does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever.
These materials are not an offer of securities for sale in the United States. The securities to which these materials relate have not been registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States.
